Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10916358 | Nuclear Medicine and Biology | 2005 | 8 Pages |
Abstract
A straightforward method for the preparation of no-carrier-added (n.c.a.) [18F]flumazenil via standard nucleophilic radiofluorination of the corresponding nitro-analog Ro 15-2344 has been developed. The labeling was performed by employing the K18F/kryptofix complex in DMF at 160°C for 30 min and equimolar ratio [K/K2.2.2]+18Fâ/precursor. Under these conditions, an 18F incorporation rate into flumazenil was in the range of 55-60%. The final product was isolated by HPLC purification within a total synthesis time of 75 min and a radiochemical yield of about 30% (EOB). Human post-mortem whole-hemisphere autoradiography of brain sections demonstrated selective uptake of the radioligand in the areas of high density of the central benzodiazepine receptors (BZR). PET studies in a cynomolgus monkey and metabolite studies by HPLC demonstrated similar results by [18F]flumazenil as for [11C]flumazenil. In blocking experiments, almost all radioactivity was inhibited by the addition of unlabeled flumazenil. [18F]Flumazenil is a suitable radioligand for PET assessment of the BZR.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Nikolaj N. Ryzhikov, Nicholas Seneca, Raisa N. Krasikova, Natalia A. Gomzina, Evgeny Shchukin, Olga S. Fedorova, Dmitrij A. Vassiliev, Balázs Gulyás, HÃ¥kan Hall, Ivanka Savic, Christer Halldin,